Yasim Rahimi

Yasmeen Rahimi, Ph.D., is Managing Director and Senior Research Analyst at Piper Sandler, specializing in biotechnology equity research with coverage of companies such as Prometheus Biosciences, Crinetics Pharmaceuticals, and Soleno Therapeutics. She has issued over 800 stock ratings, with a success rate of 36% and an average return of -0.8% per rating, including standout calls such as a 681% return on Prometheus Biosciences. Rahimi began her Wall Street career as a research associate at H.C. Wainwright & Co. and Guggenheim Securities, later serving as senior analyst and co-head of biotech research at ROTH Capital Partners before joining Piper Sandler in July 2020. She holds a Ph.D. in medicine from Indiana University, an M.S. in bioanalytical chemistry from Purdue University, a B.A. from Butler University, and is registered with FINRA, holding applicable securities licenses.